EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Insulin‐like growth factor binding protein‐2 and glucose‐regulated protein 78 kDa : Potential biomarkers affect prognosis in IDH ‐wildtype glioblastoma patients

Abigail J Harland iD, Claire M Perks iD, Paul White iD, Kathreena M Kurian iD, Hannah R Barber iD

Cancer Medicine · 2023

DOI: 10.1002/cam4.6071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Abigail J Harland und 4 weiteren Autor:innen. Beteiligte Einrichtung: Brain Tumour Research Centre, Bristol Medical School, University of Bristol, Bristol, UK. Hauptthemen laut MEDLINE: Glioblastoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The overall survival of IDH ‐wildtype glioblastoma patients is poor despite best available treatments. There is an urgent need for new biomarkers to inform more precise disease stratification. Previous studies have identified insulin‐like growth factor binding protein‐2 (IGFBP‐2) as a potential biomarker for glioblastoma diagnosis and therapeutic targeting. Other studies have indicated links between the insulin‐like growth factor (IGF) axis and tumorigenic functions of a molecular chaperone glucose related protein of 78 kDa (GRP78). We aimed to interrogate the oncogenic effects of IGFBP‐2 and GRP78 in our glioma stem cell (GSC) lines and clinical cohort.

Methods

Immunoblotting, reverse transcription quantitative real‐time PCR were used to quantify protein and mRNA levels derived from GSCs and non‐malignant neural stem cells (NSCs). Microarray analysis was used to compare the differences in IGFBP‐2 ( IGFBP‐2 ) and GRP78 (HSPA5) transcript expression between NSCs, GSCs and adult human cortex samples. Immunohistochemistry was used to quantify IGFBP‐2 and GRP78 expression in IDH ‐wildtype glioblastoma tissue sections ( n = 92) and clinical implications assessed using survival analysis. Finally, the relationship between IGFBP‐2 and GRP78 was further explored molecularly using coimmunoprecipitation.

Results

Here, we demonstrate that IGFBP‐2 and HSPA5 mRNA is overexpressed in GSCs and NSCs in comparison to non‐malignant brain tissue. We also determined a relationship in which G144 and G26 GSCs expressed higher IGFBP‐2 protein and mRNA than GRP78, and this was reversed in mRNA isolated from adult human cortex samples. Clinical cohort analysis revealed that Glioblastomas with high IGFBP‐2 protein expression paired with low GRP78 protein expression were significantly associated with a much shorter survival time (Median = 4 months, p = 0.019) compared with 12‐14 months for any other combination of high/low protein expression.

Conclusions

Inverse levels of IGFBP‐2 and GRP78 may be adverse clinical prognostic markers in IDH ‐wildtype glioblastoma. Further interrogation of the mechanistic link between IGFBP‐2 and GRP78 may be important for rationalisation of their potential as biomarkers and therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaAdultHumansBiomarkersEndoplasmic Reticulum Chaperone BiPInsulin-Like Growth Factor Binding Protein 2Insulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IPrognosisRNA, MessengerIsocitrate Dehydrogenase

Stichwörter der Autor:innen

biomarkerscancer stem cellsprognosissurvival

Substanzen

BiomarkersEndoplasmic Reticulum Chaperone BiPInsulin-Like Growth Factor Binding Protein 2Insulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IRNA, MessengerIGFBP2 protein, humanHSPA5 protein, humanIDH1 protein, humanIsocitrate Dehydrogenase

Autor:innen und Institutionen

  • Brain Tumour Research Centre, Bristol Medical School, University of Bristol, Bristol, UK.
  • IGFs & Metabolic Endocrinology Group, Bristol Medical School, Translational Health Sciences, University of Bristol, Southmead Hospital, Bristol, UK.
  • Faculty of Health Sciences, University of the West England, Bristol, UK.

ORCID-Profile: Abigail J Harland, Claire M Perks, Paul White, Kathreena M Kurian, Hannah R Barber

Zitieren

APA

Harland, A. J., Perks, C. M., White, P., Kurian, K. M., & Barber, H. R. (2023). Insulin‐like growth factor binding protein‐2 and glucose‐regulated protein 78 kDa : Potential biomarkers affect prognosis in IDH ‐wildtype glioblastoma patients. Cancer Medicine. https://doi.org/10.1002/cam4.6071

Vancouver

Harland AJ, Perks CM, White P, Kurian KM, Barber HR. Insulin‐like growth factor binding protein‐2 and glucose‐regulated protein 78 kDa : Potential biomarkers affect prognosis in IDH ‐wildtype glioblastoma patients. Cancer Medicine. 2023. doi:10.1002/cam4.6071

BibTeX
@article{Harland2023,
  author = {Harland, Abigail J and Perks, Claire M and White, Paul and Kurian, Kathreena M and Barber, Hannah R},
  title = {Insulin‐like growth factor binding protein‐2 and glucose‐regulated protein 78 kDa : Potential biomarkers affect prognosis in IDH ‐wildtype glioblastoma patients},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6071}
}
Kostenlos starten →